Marpai Announces Virta as Diabetes Premium Health Partner
Marpai (Nasdaq: MRAI) announced the addition of Virta Health as a Premium Health Partner to enhance diabetes management for its health plan members. This partnership aims to provide effective solutions for reversing type 2 diabetes, addressing the growing issue that affects nearly 133 million Americans. Virta's approach focuses on sustainable health improvements without the typical risks associated with medications. Marpai's Proactive Targeted Health Interventions will make Virta's services available to all members upon renewal or new enrollment beginning January 1, 2023.
- Partnership with Virta Health to improve diabetes management.
- Aiming to reduce health costs for employers through effective diabetes intervention.
- Virta's proven success in diabetes reversal could enhance member health outcomes.
- None.
Marpai adds proven diabetes leader to its Proactive Targeted Health Interventions service to improve outcomes for health plan members with diabetes
NEW YORK, Nov. 16, 2022 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an AI-technology company transforming self-funded employer health plans, announces the addition of Virta Health as a Premium Health Partner to improve health outcomes for health plan members with diabetes. Virta offers a breakthrough approach that has proven to reverse type 2 diabetes and other chronic metabolic diseases safely and sustainably and without the risks, costs, or side effects of medications or surgery.
According to the CDC, nearly 133 million Americans live with either diabetes or prediabetes and the number is growing. An estimated 37.3 million have diabetes (
"Diabetes is a highly prevalent, costly condition across our member populations. It represents a disproportionately high amount of health plan costs and is a top priority to address for our clients," says Marpai CEO, Edmundo Gonzalez. He adds, "Virta is a proven, high impact solution that effectively helps people lower their blood sugar and lose weight while also often reducing or even eliminating the need for medications, including insulin."
Under its universal Marpai Cares offering for self-funded health plans, Marpai delivers Proactive Targeted Health Interventions aimed at improving health outcomes and trajectories for at-risk health plan members. Using advanced AI, Marpai identifies at-risk members with a high potential for engaging clinical treatment, and matches them to a proven, clinical solution. After rigorous analysis by Marpai data scientists and clinicians, Virta has been selected as the clinical solution for treating diabetes.
"Marpai is focused on driving better member health, which also lowers costs for employers. That is
Virta is available within Marpai's Proactive Targeted Health Intervention feature to all current Marpai members upon renewal and all new members to Marpai after 1/1/2023.
For more information visit www.marpaihealth.com, www.virtahealth.com or for investors https://ir.marpaihealth.com.
Marpai, Inc. (Nasdaq: MRAI) is a technology company bringing AI-powered health plan services to employers that directly pay for employee health benefits. Primarily competing in the
Virta Health helps people reverse type 2 diabetes and other chronic conditions. Current approaches manage disease progression through increased medication use and infrequent doctor visits. Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts. In clinical studies,
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding revenues, employee lives and cash. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses the expected benefits to be derived by clients using its solution, the benefits that may be derived from the Virta solution. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise. More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
View original content:https://www.prnewswire.com/news-releases/marpai-announces-virta-as-diabetes-premium-health-partner-301679781.html
SOURCE Marpai
FAQ
What is Marpai's new partnership about?
When will Virta Health services be available to Marpai members?
What impact does this partnership have for Marpai's members?
What percentage of Americans are affected by diabetes?